FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908315212> ?p ?o ?g. }

• W2908315212 endingPage "e205" @default.
• W2908315212 startingPage "743" @default.
• W2908315212 abstract "The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its first stage for poor activity.Androgen receptors (AR) are expressed in most breast cancers, and AR-agonists have some activity in these neoplasms. We investigated the safety and activity of the androgen precursor dehydroepiandrosterone (DHEA) in combination with an aromatase inhibitor (AI) in patients with AR-positive metastatic breast cancer (MBC).A two-stage phase II study was conducted in two patient cohorts, one with estrogen receptor (ER)-positive (resistant to AIs) and the other with triple-negative MBC. DHEA 100 mg/day was administered orally. The combination with an AI aimed to prevent the conversion of DHEA into estrogens. The main endpoint was the clinical benefit rate. The triple-negative cohort was closed early.Twelve patients with ER-positive MBC were enrolled. DHEA-related adverse events, reported in four patients, included grade 2 fatigue, erythema, and transaminitis, and grade 1 drowsiness and musculoskeletal pain. Clinical benefit was observed in one patient with ER-positive disease whose tumor had AR gene amplification. There was wide inter- and intra-patient variation in serum levels of DHEA and its metabolites.DHEA showed excellent safety but poor activity in MBC. Although dose and patient selection could be improved, high serum level variability may hamper further DHEA development in this setting." @default.
• W2908315212 created "2019-01-11" @default.
• W2908315212 creator A5000297270 @default.
• W2908315212 creator A5005398528 @default.
• W2908315212 creator A5024279311 @default.
• W2908315212 creator A5028089756 @default.
• W2908315212 creator A5036497463 @default.
• W2908315212 creator A5040127317 @default.
• W2908315212 creator A5040885322 @default.
• W2908315212 creator A5045454738 @default.
• W2908315212 creator A5047952050 @default.
• W2908315212 creator A5053172573 @default.
• W2908315212 creator A5056227990 @default.
• W2908315212 creator A5070357793 @default.
• W2908315212 creator A5071229035 @default.
• W2908315212 creator A5073387586 @default.
• W2908315212 creator A5074230324 @default.
• W2908315212 creator A5074934807 @default.
• W2908315212 creator A5075055655 @default.
• W2908315212 creator A5084021572 @default.
• W2908315212 creator A5088488154 @default.
• W2908315212 creator A5089813198 @default.
• W2908315212 date "2018-12-27" @default.
• W2908315212 modified "2023-10-14" @default.
• W2908315212 title "Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer" @default.
• W2908315212 cites W1526282183 @default.
• W2908315212 cites W1653672494 @default.
• W2908315212 cites W1885639867 @default.
• W2908315212 cites W1930926117 @default.
• W2908315212 cites W1965370016 @default.
• W2908315212 cites W1966758596 @default.
• W2908315212 cites W1993292496 @default.
• W2908315212 cites W1995385187 @default.
• W2908315212 cites W1996472207 @default.
• W2908315212 cites W2004801894 @default.
• W2908315212 cites W2011411875 @default.
• W2908315212 cites W2013147142 @default.
• W2908315212 cites W2025785620 @default.
• W2908315212 cites W2026268878 @default.
• W2908315212 cites W2026741948 @default.
• W2908315212 cites W2029673044 @default.
• W2908315212 cites W2033535637 @default.
• W2908315212 cites W2033716106 @default.
• W2908315212 cites W2037425193 @default.
• W2908315212 cites W2038706132 @default.
• W2908315212 cites W2045154771 @default.
• W2908315212 cites W2046850438 @default.
• W2908315212 cites W2049112448 @default.
• W2908315212 cites W2058850167 @default.
• W2908315212 cites W2079279434 @default.
• W2908315212 cites W2079798078 @default.
• W2908315212 cites W2103038661 @default.
• W2908315212 cites W2106559777 @default.
• W2908315212 cites W2107617686 @default.
• W2908315212 cites W2111393163 @default.
• W2908315212 cites W2117319311 @default.
• W2908315212 cites W2120644077 @default.
• W2908315212 cites W2123210834 @default.
• W2908315212 cites W2130095506 @default.
• W2908315212 cites W2131913049 @default.
• W2908315212 cites W2136879321 @default.
• W2908315212 cites W2140313736 @default.
• W2908315212 cites W2143814746 @default.
• W2908315212 cites W2145801998 @default.
• W2908315212 cites W2156552325 @default.
• W2908315212 cites W2158465395 @default.
• W2908315212 cites W2159107339 @default.
• W2908315212 cites W2164848873 @default.
• W2908315212 cites W2167019139 @default.
• W2908315212 cites W2168878790 @default.
• W2908315212 cites W2279481158 @default.
• W2908315212 cites W2287079134 @default.
• W2908315212 cites W235469800 @default.
• W2908315212 cites W2396062653 @default.
• W2908315212 cites W2416798468 @default.
• W2908315212 cites W2510574450 @default.
• W2908315212 cites W2593628479 @default.
• W2908315212 cites W2594049437 @default.
• W2908315212 cites W2594248628 @default.
• W2908315212 cites W2615453589 @default.
• W2908315212 cites W27403733 @default.
• W2908315212 cites W2767344316 @default.
• W2908315212 cites W2784775153 @default.
• W2908315212 cites W3090217457 @default.
• W2908315212 cites W79337569 @default.
• W2908315212 cites W99378873 @default.
• W2908315212 doi "https://doi.org/10.1634/theoncologist.2018-0243" @default.
• W2908315212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6656524" @default.
• W2908315212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30591548" @default.
• W2908315212 hasPublicationYear "2018" @default.
• W2908315212 type Work @default.
• W2908315212 sameAs 2908315212 @default.
• W2908315212 citedByCount "6" @default.
• W2908315212 countsByYear W29083152122019 @default.
• W2908315212 countsByYear W29083152122021 @default.
• W2908315212 countsByYear W29083152122022 @default.
• W2908315212 countsByYear W29083152122023 @default.
• W2908315212 crossrefType "journal-article" @default.

• next